Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report) saw unusually-high trading volume on Thursday . Approximately 1,088,336 shares changed hands during trading, an increase of 75% from the previous session's volume of 622,865 shares.The stock last traded at $16.01 and had previously closed at $14.85.
Analyst Upgrades and Downgrades
DAWN has been the topic of a number of recent research reports. Piper Sandler reaffirmed an "overweight" rating and set a $40.00 price target on shares of Day One Biopharmaceuticals in a research report on Tuesday, March 26th. Oppenheimer reaffirmed a "market perform" rating on shares of Day One Biopharmaceuticals in a research report on Tuesday, February 27th. Finally, The Goldman Sachs Group dropped their price target on Day One Biopharmaceuticals from $50.00 to $44.00 and set a "buy" rating on the stock in a research report on Tuesday, February 27th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $40.60.
Read Our Latest Stock Report on Day One Biopharmaceuticals
Day One Biopharmaceuticals Trading Up 6.1 %
The business has a fifty day moving average of $15.24 and a 200-day moving average of $13.68. The firm has a market cap of $1.38 billion, a PE ratio of -6.62 and a beta of -1.48.
Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last issued its quarterly earnings data on Monday, February 26th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.57) by ($0.07). On average, equities analysts forecast that Day One Biopharmaceuticals, Inc. will post -2.66 EPS for the current year.
Insider Buying and Selling
In related news, insider Samuel C. Blackman sold 2,258 shares of the stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $15.25, for a total transaction of $34,434.50. Following the sale, the insider now owns 1,244,662 shares of the company's stock, valued at approximately $18,981,095.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 2,258 shares of the firm's stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $15.25, for a total value of $34,434.50. Following the sale, the insider now owns 1,244,662 shares of the company's stock, valued at approximately $18,981,095.50. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Samuel C. Blackman sold 10,000 shares of the firm's stock in a transaction dated Monday, March 25th. The shares were sold at an average price of $16.01, for a total value of $160,100.00. Following the completion of the sale, the insider now directly owns 1,184,662 shares in the company, valued at approximately $18,966,438.62. The disclosure for this sale can be found here. In the last quarter, insiders have sold 45,781 shares of company stock valued at $722,960. Corporate insiders own 8.40% of the company's stock.
Institutional Trading of Day One Biopharmaceuticals
Several institutional investors and hedge funds have recently modified their holdings of DAWN. China Universal Asset Management Co. Ltd. raised its holdings in shares of Day One Biopharmaceuticals by 130.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 2,226 shares of the company's stock valued at $27,000 after acquiring an additional 1,262 shares in the last quarter. Quest Partners LLC bought a new position in shares of Day One Biopharmaceuticals during the 4th quarter valued at about $29,000. Quintet Private Bank Europe S.A. increased its position in shares of Day One Biopharmaceuticals by 43.2% during the 4th quarter. Quintet Private Bank Europe S.A. now owns 3,313 shares of the company's stock valued at $48,000 after purchasing an additional 1,000 shares during the last quarter. Ameritas Investment Partners Inc. increased its position in shares of Day One Biopharmaceuticals by 87.3% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 4,066 shares of the company's stock valued at $49,000 after purchasing an additional 1,895 shares during the last quarter. Finally, Quantbot Technologies LP bought a new position in shares of Day One Biopharmaceuticals during the 2nd quarter valued at about $51,000. Hedge funds and other institutional investors own 87.95% of the company's stock.
About Day One Biopharmaceuticals
(
Get Free Report)
Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.
Recommended Stories
Before you consider Day One Biopharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Day One Biopharmaceuticals wasn't on the list.
While Day One Biopharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
